« All Events

Portal Therapeutics webinar

June 23

On Tuesday, June 23, Portal Therapeutics (a @GondolaBio affiliate company) is hosting an in-depth webinar reviewing the Phase 2a GATEWAY study data for PORT-77 in erythropoietic protoporphyria (EPP).

For clinicians managing rare porphyrias, this session will offer valuable insights into:

  • The latest clinical safety and efficacy data.
  • PORT-77’s mechanism of action.
  • Upcoming clinical development pathways for both EPP and X-linked protoporphyria (XLP).

Don’t miss the opportunity to engage with the team behind the data and discuss the future landscape of EPP management.

Secure your spot here: https://gondolabio.zoom.us/webinar/register/WN_q99sTmgZSYaoC3My4GTeeQ

PORT-77 is an investigational agent and has not been approved by any global health authorities.

Details